To include your compound in the COVID-19 Resource Center, submit it here.

Farletuzumab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE